Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

315 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial.
Molina JM, Journot V, Morand-Joubert L, Yéni P, Rozenbaum W, Rancinan C, Fournier S, Morlat P, Palmer P, Dupont B, Goujard C, Dellamonica P, Collin F, Poizot-Martin I, Chene G; ALIZE (Agence Nationale de Recherches sur le SIDA 099) Study Team. Molina JM, et al. Among authors: yeni p. J Infect Dis. 2005 Mar 15;191(6):830-9. doi: 10.1086/428091. Epub 2005 Feb 10. J Infect Dis. 2005. PMID: 15717256 Clinical Trial.
Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (novavir trial).
Joly V, Flandre P, Meiffredy V, Brun-Vezinet F, Gastaut JA, Goujard C, Remy G, Descamps D, Ruffault A, Certain A, Aboulker JP, Yeni P; Novavir Study Group. Joly V, et al. Among authors: yeni p. Antimicrob Agents Chemother. 2002 Jun;46(6):1906-13. doi: 10.1128/AAC.46.6.1906-1913.2002. Antimicrob Agents Chemother. 2002. PMID: 12019107 Free PMC article. Clinical Trial.
Nevirapine or lamivudine plus stavudine and indinavir: examples of 2-class versus 3-class regimens for the treatment of human immunodeficiency virus type 1.
Launay O, Gérard L, Morand-Joubert L, Flandre P, Guiramand-Hugon S, Joly V, Peytavin G, Certain A, Lévy C, Rivet S, Jacomet C, Aboulker JP, Yéni P; Agence Nationale de Recherches sur le SIDA (ANRS) 081 Study Group. Launay O, et al. Among authors: yeni p. Clin Infect Dis. 2002 Nov 1;35(9):1096-105. doi: 10.1086/342694. Epub 2002 Oct 15. Clin Infect Dis. 2002. PMID: 12384844 Clinical Trial.
Evolution of human immunodeficiency virus type 1 (HIV-1) resistance mutations in nonnucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1-infected patients switched to antiretroviral therapy without NNRTIs.
Joly V, Descamps D, Peytavin G, Touati F, Mentre F, Duval X, Delarue S, Yeni P, Brun-Vezinet F. Joly V, et al. Among authors: yeni p. Antimicrob Agents Chemother. 2004 Jan;48(1):172-5. doi: 10.1128/AAC.48.1.172-175.2004. Antimicrob Agents Chemother. 2004. PMID: 14693536 Free PMC article.
Contribution of cellular HIV-1 DNA quantification to the efficacy analysis of antiretroviral therapy: a randomized comparison of 2 regimens, including 3 drugs from 2 or 3 classes (TRIANON, ANRS 081).
Morand-Joubert L, Marcellin F, Launay O, Guiramand-Hugon S, Gérard L, Yeni P, Aboulker JP; Agence Nationale de Recherches sur le SIDA 081 Study Group. Morand-Joubert L, et al. Among authors: yeni p. J Acquir Immune Defic Syndr. 2005 Mar 1;38(3):268-76. J Acquir Immune Defic Syndr. 2005. PMID: 15735443 Clinical Trial.
315 results